Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Kobayashi K, Daizumoto K, Fukuhara H, Ohira S, Katayama S, Shimizu R, Takamoto A, Nishimura K, Ikeda K, Nagami T, Hayashida Y, Hirama H, Naito H, Tomida R, Sasaki Y, Yamamoto S, Shimizu S, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: fukuhara h. Jpn J Clin Oncol. 2024 Feb 7;54(2):167-174. doi: 10.1093/jjco/hyad143. Jpn J Clin Oncol. 2024. PMID: 37840362
Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, Daizumoto K, Katayama S, Shimizu R, Nishimura K, Nagami T, Hayashida Y, Hirama H, Takamoto A, Dainichi T, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: fukuhara h. Int J Clin Oncol. 2022 Aug;27(8):1348-1355. doi: 10.1007/s10147-022-02183-z. Epub 2022 May 20. Int J Clin Oncol. 2022. PMID: 35596089
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: fukuhara h. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474. Online ahead of print. Int J Urol. 2024. PMID: 38687165
Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
Yamada Y, Fujii Y, Kakutani S, Kimura N, Sugimoto K, Hakozaki Y, Sugihara T, Takeshima Y, Kawai T, Nakamura M, Kamei J, Taguchi S, Akiyama Y, Sato Y, Yamada D, Urabe F, Miyazaki H, Enomoto Y, Fukuhara H, Nakagawa T, Fujimura T, Kume H. Yamada Y, et al. Among authors: fukuhara h. Sci Rep. 2024 Mar 31;14(1):7607. doi: 10.1038/s41598-024-58279-1. Sci Rep. 2024. PMID: 38556562 Free PMC article.
Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1.
Ozawa T, Ikeda Y, Chen L, Suzuki R, Hoshino A, Noguchi A, Kita S, Anraku Y, Igarashi E, Saga Y, Inasaki N, Taminishi S, Sasaki J, Kirita Y, Fukuhara H, Maenaka K, Hashiguchi T, Fukuhara T, Hirabayashi K, Tani H, Kishi H, Niimi H. Ozawa T, et al. Among authors: fukuhara h. Structure. 2024 Mar 7;32(3):263-272.e7. doi: 10.1016/j.str.2023.12.013. Epub 2024 Jan 15. Structure. 2024. PMID: 38228146
Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis.
Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Yamashita H, Nakagawa K, Abe O, Fukuhara H, Kume H. Noda M, et al. Among authors: fukuhara h. Strahlenther Onkol. 2024 Jan 5. doi: 10.1007/s00066-023-02192-5. Online ahead of print. Strahlenther Onkol. 2024. PMID: 38180494
586 results